Skip to Main Content

Hello, everyone, and how are you today? We are doing just fine, thank you, despite the steamy heat surrounding the Pharmalot campus. Our formula for keeping cool is to turn up the cooling machine and keep some cold cups of stimulation at hand. After all, there is much to be done. On that note, let us proceed. Here is the usual menu of interesting items to help you along. Hope your day is productive and try not to sweat …

ClinicalTrials.gov does not require trial sponsors to disclose charges to patients and critics say this allows the site to become a marketing tool for pay-to-play research, Kaiser Health News reports. “If you’re going to be charging patients for the opportunity to be involved in the study, they should not be allowed to be listed … or at least the cost should be listed on the site,” says Alison Bateman-House, a postdoctoral fellow in medical ethics at the New York University School of Medicine.

BioMarin released additional evidence supporting its gene therapy for restoring the blood-clotting ability of patients with hemophilia A, TheStreet tells us. The company now says it will start another study that could be used to get the treatment approved by regulators in the US and Europe. If the treatment is approved, the drug would be the first gene therapy used to treat — and potentially cure — patients with hemophilia A.

advertisement

The Irish government reached deal with the Irish Pharmaceutical Healthcare Association to reduce the costs of drugs that are paid for by the Health Service Executive, The Irish Times reports. The government claims the deal will save about $830 million, but opponents say it will block access to biosimilars and generics, because the trade group representing companies making these medicines is not part of the agreement.

Teva Pharmaceuticals agreed to sell the rights and related assets to 79 medicines to settle charges that its proposed $40.5 billion acquisition of Allergan’s generic drug business would be anti-competitive. The agreement with the US Federal Trade Commission requires Teva to sell the drugs to 11 different companies. The FTC called this the largest such divestiture involving a drug maker in a merger case overseen by the agency.

advertisement

The US Food and Drug Administration plans to hold an advisory committee meeting in September to review a trial exploring psychiatric side effects associated with Pfizer’s Chantix pill, which is used to help people quit smoking.

AstraZeneca’s chief executive declined to comment on whether the drug maker could become a takeover target again after an analyst suggested Novartis may be interested in making an offer, Reuters writes.

Meanwhile, David Ricks, who takes over as Eli Lilly chief executive in January, says he will accelerate deal making, Reuters reports. Ricks, 49, has served since 2012 as president of Lilly Bio-Medicines.

Pfizer is settling a securities class-action lawsuit accusing it of hiding information about studies suggesting use of the Celebrex and Bextra drugs may increase risks of heart attacks and strokes, Bloomberg News tells us.

The UK’s Medicines and Healthcare products Regulatory Agency will no longer require drug makers to submit regular safety surveillance compliance reports, unless specifically requested by the agency, Regulatory Focus says.

The plaintiff in a bellwether lawsuit against Johnson & Johnson can introduce expert testimony that acetaminophen, the key ingredient in Tylenol, can cause liver damage, the Legal Intelligencer reports.

Chinese health authorities plan to track the purchase and distribution of vaccines and conduct random checks at hospitals and clinics after an investigation into a nearly $90 million black market, BioSpectrum Asia says.

The Ice Bucket Challenge that went viral two years ago and raised hundreds of millions of dollars helped identify a new gene behind Lou Gehrig’s disease, Reuters reports.

Pfizer won approval from a bankruptcy court to buy the assets of Bind Therapeutics for $40 million, according to the Wall Street Journal.

Teva Pharmaceuticals and Mylan have shown interest in a Brazilian generic joint venture in which Pfizer has a 40 percent stake, Reuters reports.

Comments are closed.